Clinical Trials
7 trialsNCT07622186 2026-06-03
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT07622706 2026-06-03
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07517640 2026-04-08
Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT07482605 2026-03-20
Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
Jiangmen Central Hospital
Phase 2 Not yet recruiting
NCT07365410 2026-01-26
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07314216 2026-01-06
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
Hunan Cancer Hospital
Phase 2 Not yet recruiting
NCT07193160 2025-09-25
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
Fudan University
Phase 2 Not yet recruiting